Project Grant HT94252310907
Award Date
9/15/23
Completion Date
9/14/27
Dollars Obligated
$5.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Defense Health Agency (DHA) Project Grant award for $4,509,475.00, granted on Sep 15, 2023 under the Military Medical Research and Development program (CFDA 12.420), supports a 4-year research project titled "Optimizing a Surveillance Strategy to Tackle Breast Cancer Dormancy and Minimal Residual Disease" to be conducted by the Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The objective of this research is...
This $520,259 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research at Carnegie Mellon University to develop a liquid biopsy-based approach for predicting pathological complete response in breast cancer patients. The project aims to leverage extracellular vesicles and advanced sequencing techniques to enable ultrasensitive detection of breast cancer-specific genetic mutations. As a...
This federal Project Grant award in the amount of $1,605,638.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, a private research university and academic medical center. The grant funding supports research aimed at developing new methods for immune targeting of dormant tumor...
The Trustees of the University of Pennsylvania were awarded a $1,624,578 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research into the mechanisms of mammary tumor recurrence from July 1, 2021 to June 30, 2024. Through this funding, the University of Pennsylvania will investigate medical solutions for breast cancer recurrence on the battlefield and for the American public...
This federal Project Grant award, valued at $161,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "BREAST CANCER BRAIN METASTASES: INTEGRATING IMMUNOGENOMIC AND PHENOTYPIC VULNERABILITIES TO IMPROVE OUTCOMES", will support advanced biomedical research focused on transforming healthcare for military service members and the broader public. The award, with a performance period from April 1, 2025 to...
The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
The U.S. Department of Defense's Defense Health Agency has awarded a $1,255,505 Project Grant to Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, under the Military Medical Research and Development program (CFDA 12.420). The grant, which has a performance period of July 1, 2024 to June 30, 2027, is for the development of a unique small molecule for the treatment of triple-negative breast cancer. As a leading academic medical center, Penn State has...
This federal Project Grant award for $1,305,270.00, titled "OVARIAN CANCER ACADEMY: ADVANCING OVARIAN CANCER RESEARCH THROUGH MENTORSHIP, NETWORKING, AND COLLABORATIONS", was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award will support advanced biomedical research focused on transforming healthcare for military service members and the public through the University of Pennsylvania's Clinical Practices. Key...